Investigational Drug Details
| Drug ID: | D113 |
| Drug Name: | Dihydromyricetin |
| Synonyms: | (+)-ampelopsin; (+)-dihydromyricetin; Ampelopsin; Ampeloptin; Telocapil |
| Type: | Chemical drug |
| DrugBank ID: | DB15645 |
| DrugBank Description: | Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus). |
| PubChem ID: | 161557 |
| CasNo: | 27200-12-0 |
| Repositioning for NAFLD: | No |
| SMILES: | O=C1c2c(O[C@@H]([C@H]1O)c1cc(O)c(c(c1)O)O)cc(cc2O)O |
| Structure: |
|
| InChiKey: | KJXSIXMJHKAJOD-LSDHHAIUSA-N |
| Molecular Weight: | 320.253 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (ChiCTR-TRC-12002377) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0936 | ChiCTR-TRC-12002377 | Pilot study | Not Recruiting | No Results Available | 16/07/2012 | 18 April 2017 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00744 | 34981470 | Adv Exp Med Biol | The Effect of Herbal Medicine and Natural Bioactive Compounds on Plasma Adiponectin: A Clinical Review. | Details |
| A02531 | 34339914 | Biomed Pharmacother | Molecular mechanisms and therapeutic implications of dihydromyricetin in liver disease. | Details |
| A06996 | 32666969 | Food Funct | Ameliorative effects and molecular mechanisms of vine tea on western diet-induced NAFLD. | Details |
| A08181 | 32217100 | Biochem Pharmacol | Modulation of SIRT1-mediated signaling cascades in the liver contributes to the amelioration of nonalcoholic steatohepatitis in high fat fed middle-aged LDL receptor knockout mice by dihydromyricetin. | Details |
| A09124 | 31866404 | Eur J Pharmacol | Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases. | Details |
| A14647 | 29310441 | Antioxid Redox Signal | Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling. | Details |
| A18247 | 27265384 | Life Sci | Dihydromyricetin ameliorates oleic acid-induced lipid accumulation in L02 and HepG2 cells by inhibiting lipogenesis and oxidative stress. | Details |
| A20316 | 26032587 | Pharmacol Res | Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. | Details |
| A29150 | 34503544 | Nutr Metab (Lond) | Dihydromyricetin attenuates palmitic acid-induced oxidative stress by promoting autophagy via SIRT3-ATG4B signaling in hepatocytes. | Details |
| A45043 | 26318761 | Pharmacol Res | Similarity between studies of dihydromyricetin and reservatrol for NAFLD. | Details |
| A45048 | 26299475 | Pharmacol Res | Response to letter to the Editor: "Similarity between studies of dihydromyricetin and resveratrol for NAFLD". | Details |
| A46962 | 32267550 | Alcohol Clin Exp Res | Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism. | Details |
| A50039 | 35551031 | Food Chem | A designed self-microemulsion delivery system for dihydromyricetin and its dietary intervention effect on high-fat-diet fed mice. | Details |
| A51137 | 35527487 | Nan Fang Yi Ke Da Xue Xue Bao | [Dihydromyricetin reduces lipid accumulation in LO2 cells via AMPK/mTOR-mediated lipophagy pathway and inhibits HepG2 cell proliferation in vitro]. | Details |